The changes in FIGO staging for carcinoma of the cervix uteri

Authors: B. Sehnal 1;  J. Sláma 2;  E. Kmoníčková 3;  O. Dubová 1;  M. Zikán 1
Authors‘ workplace: Onkogynekologické centrum, Gynekologicko-porodnická klinika, Nemocnice Na Bulovce a 1. lékařské fakulty Univerzity Karlovy, Praha, přednosta prof. MUDr. M. Zikán, Ph. D. 1;  Onkogynekologické centrum, Gynekologicko-porodnická klinika Všeobecné fakultní nemocnice a 1. lékařské fakulty Univerzity Karlovy, Praha, přednosta prof. MUDr. A. Martan, DrSc. 2;  Ústav radiační onkologie, Komplexní onkologické centrum, Nemocnice Na Bulovce, Praha, přednosta prof. MUDr. L. Petruželka, CSc 3
Published in: Ceska Gynekol 2019; 84(3): 216-221


Introduction: The carcinoma of the cervix uteri is the fourth most common cancer in women worldwide and more than 85% of these cases occur in developing countries. Altogether 822 new cases were found in the Czech Republic during 2016 which means the incidence 15,3 new diseases/100,000 women.

Objective: To provide an overview of changes in FIGO (International Federation of Gynecology and Obstetrics) staging for carcinoma of the cervix uteri with an incorporation of possible imaging methods and/or pathological findings, and clinical assessment of tumor size and extent.

Settings: Gynecologic Oncology Center, Department of Gynecology and Obstetrics, Hospital Na Bulovce and 1st Medical School of Charles University, Prague; Gynecologic Oncology Center, Department of Gynecology and Obstetrics, General Faculty Hospital and 1st Medical School of Charles University, Prague; Institute of Radiation Oncology, Hospital Na Bulovce, Prague.

Methods: For this review, we have used the results of studies, review articles, and guidelines of oncogynecologic organisations on the cervical cancer published in English. They were identified through a search of literature using PubMed, MEDLINE-Ovid, Scopus and Cochrane Library with the keywords. We summarize the new classification, main changes compared to the former one and their clinical impact.

Conclusion: Lateral extension measurement is removed in the stage IA, the only criterion is the measured deepest invasion <5.0 mm. Stage IB was divided into three subgroups; IB1: tumors ≥5 mm and <2 cm in greatest diameter; IB2: tumors size 2–4 cm; IB3: tumors ≥4 cm. Stage IIIC includes an assessment of retroperitoneal lymph nodes; IIIC1 if only pelvic lymph nodes are involved, IIIC2 if paraaortic nodes are infiltrated. The revised staging system does not mandate the use of a specific imaging method, lymph node biopsy, or surgical assessment of the extent of tumor. The way of assigning the stage should be recorded and reported. The presence of lymphovascular space invasion does not change the stage of a disease.


staging – FIGO – cervix uteri – ESGO


1. Baiocchi, G., de Brot, L., Faloppa, CC., et al. Is parametrectomy always necessary in early-stage cervical cancer? Gynecol Oncol, 2017, 146(1), p. 16–19.

2. Balleyguier, C., Sala, E., Da Cunha, T., et al. Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology. Eur Radiol, 2011, 21, 5, p. 1102–1110.

3. Bhatla, N., Berek, JS., Cuello Fredes, M., et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet, 2019, doi: 10.1002/ijgo.12749.

4. Bray, F., Ferlay, J., Soerjomataram, I., et al. Global cancer statistics 2018: GLOBOCAN estimates of cancer incidence and mortality for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68, p. 394–424.

5. Cibula, D, Abu-Rustum, NR., Dusek, L., et al. Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis. Gynecol Oncol, 2012, 127, p. 462–466.

6. Cibula, D, McCluggage, WG. Sentinel lymph node (SLN) concept in cervical cancer: Current limitations and unanswered questions. Gynecol Oncol, 2019, 152(1), p. 202–207.

7. Epstein, E., Testa, A., Gaurilcikas, A., et al. Early-stage cervical cancer: tumor delineation by magnetic resonance imaging and ultrasound – an European multicenter trial. Gynecol Oncol, 2013, 128, 3, p. 449–453.

8. European Society of Gynecologic Oncology, ESGO. Cervical cancer guidelines. Dostupné pro členy ESGO z

9. Fischerová, D. Staging zhoubného nádoru děložního hrdla (stanovení předoperačního rozsahu onemocnění) – přehled výsledků nejnovějších ultrazvukových studií. Čes Gynek, 2014, 79, 6, s. 436–446.

10. Fischerova, D., Cibula, D. Ultrasound in gynecological cancer: Is it time for reevaluation of its uses? Curr Oncol Rep, 2015, 17, p. 28.

11. Fischerova, D., Cibula, D., Stenhova, H., et al. Transectal ultrasound and magnetic resonance imaging in staging of early cervical cancer. Int J Gynecol Cancer, 2008, 18, 4, p. 766–772.

12. Kodama, J., Fukushima, C., Kusumoto, T., et al. Stage IB1 cervical cancer patients with an MRI-measured tumor size < or = 2 cm might be candidates for less-radical surgery. Eur J Gynaecol Oncol, 2013, 34(1), p. 39–41.

13. Mladěnka, A., Sláma, J. Vakcinace proti HPV a výhled nových možností. Čes Gynek, 2018, 83(3), s. 218–225.

14. Pluta, M., Rob, L., Charvat, M., et al. Less radical surgery than radical hysterectomy in early stage cervical cancer: a pilot study. Gynecol Oncol, 2009, 113(2), p. 181–184.

15. Querleu, D., Cibula, D., Abu-Rustum, NR. 2017 Update on the Querleu-Morrow Classification of Radical Hysterectomy. Ann Surg Oncol, 2017, 24(11), p. 3406–3412.

16. Ramirez, PT., Pareja, R., Rendón, GJ., et al. Management of low-risk early-stage cervical cancer: should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care? Gynecol Oncol, 2014, 132(1), p. 254–259.

17. Rob, L., Charvat, M., Robova, H., et al. Less radical fertility-sparing surgery than radical trachelectomy in early cervical cancer. Int J Gynecol Cancer, 2007, 17(1), p. 304–310.

18. Sehnal, B., Driák, D., Kmoníčková, E., et al. Současná klasifikace zhoubných nádorů v onkogynekologii – část I. Čes Gynek, 2011, 76 (4), s. 279–284.

19. Sláma, J. Současné limity prevence karcinomu děložního hrdla v České republice. Čes Gynek, 2017, 82(6), s. 482–486.

20. Slama, J., Cerny, A., Dusek, L., et al. Results of less radical fertility-sparing procedures with omitted parametrectomy for cervical cancer: 5 years of experience. Gynecol Oncol, 2016, 142(3), p. 401–404.

21. [internetova stranka]. Česky narodni webovy portal epidemiologie nadorů. System pro vizualizaci onkologickych dat. Institut biostatistiky a analyz Lekařske a Přirodovědecke fakulty Masarykovy univerzity (IBA MU). Dostupny z: http://

22. Testa, AC., Ludovisi, M., Manfredi, R., et al. Transvaginal ultrasonography and magnetic resonance imaging for assessment of presence, size and extent of invasive cervical cancer. Ultrasound Obstet Gynecol, 2009, 34, 3, p. 335–344.

23. Weinberger, V., Dvořák, M., Haakova, L., et al. Ultrazvukový staging karcinomu děložního hrdla – návrh standardního postupu. Čes Gynek, 2014, 79, 6, s. 447–455.

24. Zhang, Q., Li, W., Kanis, MJ., et al. Oncologic and obstetrical outcomes with fertility-sparing treatment of cervical cancer: A systematic review and meta-analysis. Oncotarget, 2017, 8, p. 46580–46592.

Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine

Article was published in

Czech Gynaecology

Issue 3

2019 Issue 3

Most read in this issue
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account